<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUTAMIDE- flutamideÂ capsuleÂ </strong><br>IVAX Pharmaceuticals, Inc.<br></p></div>
<h1>FLUTAMIDE CAPSULES USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_4203a761-7bb7-413b-a875-d782cce037b7"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">WARNINGS</span></p>
<p><span class="Bold">Hepatic Injury</span></p>
<p>There have been postmarketing reports of hospitalization and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> related to <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute hepatic failure</span>. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide.</p>
<p>Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, â€œflu-likeâ€? symptoms, hyperbilirubinuria, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>. If at any time, a patient has <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests until resolution.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_37641154-a616-43dc-a245-5578e642ab9d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Flutamide Capsules USP contain flutamide, an acetanilid, nonsteroidal, orally active antiandrogen having the chemical name, Î±,Î±,Î±-Trifluoro-2-methyl-4â€™-nitro-<span class="Italics">m</span>-propionotoluidide and has the following structural formula:</p>
<div class="Figure"><img alt="Flutamide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bae781d4-7101-4008-9af2-6e76b5e1c408&amp;name=55c76073-6224-4470-9426-2d5446f0781d-01.jpg"></div>
<p>C<span class="Sub">11</span>H<span class="Sub">11</span>F<span class="Sub">3</span>N<span class="Sub">2</span>O<span class="Sub">3</span> M.W. 276.21</p>
<p>Flutamide is a buff to yellow powder. Each capsule, for oral administration, contains 125 mg flutamide and has the following inactive ingredients: black iron oxide, corn starch, D&amp;C yellow #10 aluminum lake, FD&amp;C blue #1 aluminum lake, FD&amp;C blue #2 aluminum lake, FD&amp;C red #40 aluminum lake, gelatin, lactose monohydrate, magnesium stearate, red iron oxide, sodium lauryl sulfate, titanium dioxide and yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_afd1dddc-0b90-4119-b136-fd3f37294dc8"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a56afc25-dfad-4d15-840b-017b0b4eec9e"></a><a name="section-2.1"></a><p></p>
<h2>General</h2>
<p class="First">In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g., castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b5c5027-5c4f-4a39-8135-494130fd4808"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0d8e23e-5fef-48d2-bb30-7b6441bfa81c"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">Analysis of plasma, urine, and feces following a single oral 200 mg dose of tritium-labeled flutamide to human volunteers showed that the drug is rapidly and completely absorbed. Following a single 250 mg oral dose to normal adult volunteers, the biologically active alpha-hydroxylated metabolite reaches maximum plasma concentrations in about 2 hours, indicating that it is rapidly formed from flutamide. Food has no effect on the bioavailability of flutamide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ad7b334-a4ae-406d-953f-b89dd5ef6c69"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">In male rats neither flutamide nor any of its metabolites is preferentially accumulated in any tissue except the prostate after an oral 5 mg/kg dose of <span class="Sup">14</span>C-flutamide. Total drug levels were highest 6 hours after drug administration in all tissues. Levels declined at roughly similar rates to low levels at 18 hours. The major metabolite was present at higher concentrations than flutamide in all tissues studied. Following a single 250 mg oral dose to normal adult volunteers, low plasma levels of flutamide were detected. The plasma half-life for the alpha-hydroxylated metabolite of flutamide is about 6 hours. Flutamide, <span class="Italics">in vivo</span>, at steady-state plasma concentrations of 24 to 78 ng/mL, is 94% to 96% bound to plasma proteins. The active metabolite of flutamide, <span class="Italics">in vivo</span>, at steady-state plasma concentrations of 1556 to 2284 ng/mL, is 92% to 94% bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8df7ed10-b5c2-4370-819e-bf4a26bf1186"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">The composition of plasma radioactivity, following a single 200 mg oral dose of tritium-labeled flutamide to normal adult volunteers, showed that flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration. At least 6 metabolites have been identified in plasma. The major plasma metabolite is a biologically active alpha-hydroxylated derivative which accounts for 23% of the plasma tritium 1 hour after drug administration. The major urinary metabolite is 2-amino-5-nitro-4-(trifluoromethyl)phenol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4c87603-f2a2-47a1-b9f9-4c50a44d3d12"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Bold">Excretion</span></h3>
<p class="First">Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of the dose excreted in the feces over 72 hours.</p>
<a name="id_113df19e-c0ad-4700-97fe-cb90f9e704cd"></a><table border="1" width="428.000">
<caption><span>Plasma Pharmacokinetics of Flutamide and Hydroxyflutamide in Geriatric Volunteers (mean Â± SD)</span></caption>
<col align="left" width="20.1%">
<col align="left" width="16.6%">
<col align="left" width="23.4%">
<col align="left" width="17.3%">
<col align="left" width="22.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Â </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> Single Dose </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> Steady State </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â </td>
<td class="Botrule Rrule" align="center" valign="middle"> Flutamide </td>
<td class="Botrule Rrule" align="center" valign="middle"> Hydroxyflutamide </td>
<td class="Botrule Rrule" align="center" valign="middle"> Flutamide </td>
<td class="Botrule Rrule" align="center" valign="middle"> Hydroxyflutamide </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">C<span class="Sub">max </span>(ng/mL) </td>
<td class="Botrule Rrule" align="center" valign="middle">25.2 Â± 34.2 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 894 Â± 406 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 113 Â± 213 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 1629 Â± 586 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Elimination half-life (hr) </td>
<td class="Botrule Rrule" align="center" valign="middle">- </td>
<td class="Botrule Rrule" align="center" valign="middle"> 8.1 Â± 1.3 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 7.8 </td>
<td class="Botrule Rrule" align="center" valign="middle">9.6 Â± 2.5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">T<span class="Sub">max</span> (hr) </td>
<td class="Botrule Rrule" align="center" valign="middle">1.9 Â± 0.7 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 2.7 Â± 1 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 1.3 Â± 0.7 </td>
<td class="Botrule Rrule" align="center" valign="middle">1.9 Â± 0.6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">C<span class="Sub">min </span>(ng/mL) </td>
<td class="Rrule" align="center" valign="middle"> - </td>
<td class="Rrule" align="center" valign="middle"> - </td>
<td class="Rrule" align="center" valign="middle"> - </td>
<td class="Botrule Rrule" align="center" valign="middle"> 673 Â± 316 </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67c327aa-323c-433a-8825-d729ba376527"></a><a name="section-2.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6ae42e6-c84f-4cd2-ba88-708c3157ceca"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Bold">Geriatric</span></h3>
<p class="First">Following multiple oral dosing of 250 mg t.i.d. in normal geriatric volunteers, flutamide and its active metabolite approached steady-state plasma levels (based on pharmacokinetic simulations) after the fourth flutamide dose. The half-life of the active metabolite in geriatric volunteers after a single flutamide dose is about 8.1 hours and at steady state in 9.6 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af2521cc-37c7-4e28-b09d-a71089137768"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Bold">Race</span></h3>
<p class="First">There are no known alterations in flutamide absorption, distribution, metabolism, or excretion due to race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1550436-2d99-419b-bce1-06752a826a48"></a><a name="section-2.3.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h3>
<p class="First">Following a single 250 mg dose of flutamide administered to subjects with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span>, there appeared to be no correlation between creatinine clearance and either C<span class="Sub">max</span> or AUC of flutamide. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> did not have an effect on the C<span class="Sub">max</span> or AUC of the biologically active alpha-hydroxylated metabolite of flutamide. In subjects with creatinine clearance of &lt; 29 mL/min, the half-life of the active metabolite was slightly prolonged. Flutamide and its active metabolite were not well dialyzed. Dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> is not warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d24a41f1-d66f-4a1e-932c-a95e56c26a91"></a><a name="section-2.3.4"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h3>
<p class="First">No information on the pharmacokinetics of flutamide in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is available (see <span class="Bold">BOXED WARNINGS, Hepatic Injury</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e07008fa-3df7-446b-a94f-0ef0cb7fec46"></a><a name="section-2.3.5"></a><p></p>
<h3><span class="Bold">Women, Pediatrics</span></h3>
<p class="First">Flutamide has not been studied in women or pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ebaf3a60-195f-4c93-a0da-26134654065b"></a><a name="section-2.3.6"></a><p></p>
<h3><span class="Bold">Drug-Drug Interactions</span></h3>
<p class="First">Interactions between flutamide capsules and LHRH agonists have not occurred. Increases in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> have been noted in patients receiving warfarin therapy (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8661d053-71fe-4e85-82fe-225b6c6b102a"></a><a name="section-2.3.7"></a><p></p>
<h3><span class="Bold">Clinical Studies</span></h3>
<p class="First">Flutamide has been demonstrated to interfere with testosterone at the cellular level. This can complement medical castration achieved with LHRH agonists which suppresses testicular androgen production by inhibiting luteinizing hormone secretion.</p>
<p>The effects of combination therapy have been evaluated in two studies. One study evaluated the effects of flutamide and an LHRH agonist as neoadjuvant therapy to radiation in stage B<span class="Sub">2</span>-C prostatic carcinoma and the other study evaluated flutamide and an LHRH agonist as the sole therapy in stage D<span class="Sub">2</span> metastatic carcinoma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4fdfc34b-6553-4a5a-8158-c39da570d1c1"></a><a name="section-2.3.8"></a><p></p>
<h3><span class="Bold">Stage B<span class="Sub">2</span>-C Prostatic Carcinoma</span></h3>
<p class="First">The effects of hormonal treatment combined with radiation were studied in 466 patients (231 flutamide capsules + goserelin acetate implant + radiation, 235 radiation alone) with bulky primary tumors confined to the prostate (stage B<span class="Sub">2</span>) or extending beyond the capsule (stage C), with or without pelvic node involvement.</p>
<p>In this multicentered, controlled trial, administration of flutamide capsules (250 mg t.i.d.) and goserelin acetate (3.6 mg depot) prior to and during radiation was associated with a significantly lower rate of local failure compared to radiation alone (16% vs. 33% at 4 years, <span class="Italics">P </span>&lt; 0.001). The combination therapy also resulted in a trend toward reduction in the incidence of distant <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> (27% vs. 36% at 4 years, <span class="Italics">P</span> = 0.058). Median disease-free survival was significantly increased in patients who received complete hormonal therapy combined with radiation as compared to those patients who received radiation alone (4.4 vs. 2.6 years, <span class="Italics">P </span>&lt; 0.001). Inclusion of normal PSA level as a criterion for disease-free survival also resulted in significantly increased median disease-free survival in patients receiving the combination therapy (2.7 vs. 1.5 years, <span class="Italics">P </span>&lt; 0.001).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95867952-f18c-4d71-9779-9dad14f3702f"></a><a name="section-2.3.9"></a><p></p>
<h3><span class="Bold">Stage D<span class="Sub">2</span> Prostatic Carcinoma</span></h3>
<p class="First">To study the effects of combination therapy in <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>, 617 patients (311 leuprolide + flutamide, 306 leuprolide + placebo) with previously untreated advanced prostatic carcinoma were enrolled in a large multicentered, controlled clinical trial.</p>
<p>Three and one-half years after the study was initiated, median survival had been reached. The median actuarial survival time was 34.9 months for patients treated with leuprolide and flutamide versus 27.9 months for patients treated with leuprolide alone. This 7 month increment represents a 25% improvement in overall survival time with the flutamide therapy. Analysis of progression-free survival showed a 2.6 month improvement in patients who received leuprolide plus flutamide, a 19% increment over leuprolide and placebo.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f95c1683-2a1a-4227-a3e1-56c7ca6a7ad7"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Flutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B<span class="Sub">2</span>-C and Stage D<span class="Sub">2</span> metastatic carcinoma of the prostate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d36f725b-169c-434a-8e48-c9b257808722"></a><a name="section-3.1"></a><p></p>
<h2>Stage B<span class="Sub">2</span>-C Prostatic Carcinoma</h2>
<p class="First">Treatment with flutamide capsules and the goserelin acetate implant should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3bdcdcd-d1b4-4037-b050-585bb2170532"></a><a name="section-3.2"></a><p></p>
<h2>Stage D<span class="Sub">2</span> Metastatic Carcinoma</h2>
<p class="First">To achieve benefit from treatment, flutamide capsules should be initiated with the LHRH agonist and continued until progression.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_890828a0-d973-40a2-bde2-6feeceded554"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Flutamide capsules are contraindicated in patients who are hypersensitive to flutamide or any component of this preparation.</p>
<p>Flutamide capsules are contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (baseline hepatic enzymes should be evaluated prior to treatment).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_d62cfe70-6a54-4914-94f7-af8b8eaaf7e0"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_813c07a2-d5aa-40d0-8f6b-ff0bf9ec2fb8"></a><a name="section-5.1"></a><p></p>
<h2>Hepatic Injury</h2>
<p class="First">See <span class="Bold">BOXED WARNINGS.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2940b25-ebc0-4cbe-999a-732d72ebd1fb"></a><a name="section-5.2"></a><p></p>
<h2>Use in Women</h2>
<p class="First">Flutamide capsules are for use <span class="Bold">only</span> in men. This product has no indication for women and should not be used in this population, particularly for nonserious or non-life threatening conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d3ab0cd-5517-4153-ba58-3ad45b48ae65"></a><a name="section-5.3"></a><p></p>
<h2>Fetal Toxicity</h2>
<p class="First">Flutamide may cause fetal harm when administered to a pregnant woman (see <span class="Bold">Pregnancy</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa6cd4d7-c25f-4c1b-9183-423b9dcb1a2c"></a><a name="section-5.4"></a><p></p>
<h2>Aniline Toxicity</h2>
<p class="First">One metabolite of flutamide is 4-nitro-3-fluoro-methylaniline. Several toxicities consistent with aniline exposure, including <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> have been observed in both animals and humans after flutamide administration. In patients susceptible to aniline toxicity (e.g., persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9b4128b8-0084-43ca-b7d8-2c0413de1c05"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_39a45079-3e7a-4130-8f1d-384089af014d"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">In clinical trials, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> occurred in 9% of patients receiving flutamide together with medical castration.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_90837fcf-43a3-4ac2-a855-33ddda13f49b"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be informed that flutamide capsules and the drug used for medical castration should be administered concomitantly, and that they should not interrupt their dosing or stop taking these medications without consulting their physician.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_dc80b654-0be6-4497-9f54-14498116852c"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Regular assessment of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patient's response. If PSA levels rise significantly and consistently during flutamide therapy the patient should be evaluated for clinical progression. For patients who have objective progression of disease together with an elevated PSA, a treatment-free period of antiandrogen while continuing the LHRH analogue may be considered.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_755fb03c-3885-4a3f-b469-02b6192847e9"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Increases in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time have been noted in patients receiving long-term warfarin therapy after flutamide was initiated. Therefore close monitoring of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is recommended and adjustment of the anticoagulant dose may be necessary when flutamide capsules are administered concomitantly with warfarin.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a2585e34-fb24-4730-b486-0ecc67884f0e"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 1-year dietary study in male rats, interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the testes were present in 49% to 75% of all treated rats (daily oral doses of 10, 30, and 50 mg/kg/day were administered). These produce plasma C<span class="Sub">max</span> values that are 1, 2 to 3, and 4 fold, respectively, those associated with therapeutic doses in humans. In male rats similarly dosed for 1 year, tumors were still present after 1 year of a drug-free period, but the incidences were 43% to 47%. In a 2 year carcinogenicity study in male rats, daily administration of flutamide at these same doses produced testicular interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in 91% to 95% of all treated rats as opposed to 11% of untreated control rats. Mammary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, adenocarcinomas, and fibroadenomas were increased in treated male rats at exposure levels that were 1 to 4 fold those observed during therapeutic dosing in humans. There are likewise reports of malignant breast neoplasms in men treated with flutamide capsules (see <span class="Bold">ADVERSE REACTIONS</span> section).</p>
<p>Flutamide did not demonstrate DNA modifying activity in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/Microsome Mutagenesis Assay. Dominant lethal tests in rats were negative.</p>
<p>Reduced sperm counts were observed during a 6 week study of flutamide monotherapy in normal human volunteers.</p>
<p>Flutamide did not affect estrous cycles or interfere with the mating behavior of male and female rats when the drug was administered at 25 and 75 mg/kg/day prior to mating. Males treated with 150 mg/kg/day (30 times the minimum effective antiandrogenic dose) failed to mate; mating behavior returned to normal after dosing was stopped. Conception rates were decreased in all dosing groups. Suppression of spermatogenesis was observed in rats dosed for 52 weeks at approximately 3, 8, or 17 times the human dose and in dogs dosed for 78 weeks at 1.4, 2.3, and 3.7 times the human dose.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_0857b4bf-f458-46ab-b512-268181ab7d3a"></a><a name="section-6.6"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First">Serious cardiac lesions were observed in 2/10 beagle dogs receiving 25 mg/kg/day for 78 weeks and 3/16 receiving 40 mg/kg/day for 2 to 4 years. These lesions, indicative of chronic injury and repair processes, included chronic myxomatous degeneration, intra-atrial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, myocardial acidophilic degeneration, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and perivasculitis. The doses at which these lesions occurred were associated with 2-hydroxyflutamide levels that were 1 to 12 fold greater than those observed in humans at therapeutic levels.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_197ea8b1-6212-4a2d-9b18-87163b3673d4"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_fb7ed349-12a6-47cd-b7bc-6c03ce39e7de"></a><a name="section-6.7.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects </span></h3>
<p class="First"><span class="Italics">Pregnancy Category D</span></p>
<p>There was decreased 24 hour survival in the offspring of pregnant rats treated with flutamide at doses of 30, 100, or 200 mg/kg/day (approximately 3, 9, and 19 times the human dose). A slight increase in minor variations in the development of the sternebrae and vertebrae was seen in fetuses of cats treated with two higher doses. <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">Feminization</span> of the male cats also occurred at the two higher dose levels. There was a decreased survival rate in the offspring of rabbits receiving the highest dose (15 mg/kg/day, equal to 1.4 times the human dose).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_dcd68e58-5921-47fd-8b99-fcec3dc94bd0"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_164d9f82-aeb0-4ec6-8ff4-7f021051bda9"></a><a name="section-7.1"></a><p></p>
<h2>Stage B<span class="Sub">2</span>-C Prostatic Carcinoma</h2>
<p class="First">Treatment with flutamide capsules and the goserelin acetate implant did not add substantially to the toxicity of radiation treatment alone. The following adverse experiences were reported during a multicenter clinical trial comparing flutamide capsules + goserelin acetate implant + radiation versus radiation alone. The most frequently reported (greater than 5%) adverse experiences are listed below.</p>
<p>Â </p>
<a name="id_67b5f9e4-b822-42ed-97d3-890bbd62edfc"></a><table border="single" width="479">
<col width="14.9%">
<col width="20.0%">
<col width="15.0%">
<col width="16.3%">
<col width="21.3%">
<col width="12.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Adverse Events During Acute Radiation Therapy</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><span class="Bold">Adverse Events During Late Radiation Phase</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="middle"><span class="Bold"> (within first 90 days of radiation therapy) </span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><span class="Bold"> (after 90 days of radiation therapy) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Â </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> (n = 231) </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> (n = 235) </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Â </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> (n = 231) </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> (n = 235) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Â </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> Goserelin Acetate Implant + Flutamide Capsules + Radiation </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> Radiation Only </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Â </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> Goserelin Acetate Implant + Flutamide Capsules + Radiation </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> Radiation Only </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Â </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> % All </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> % All </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Â </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> % All </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> % All </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">Rectum/large </p> bowel </td>
<td class="Botrule Rrule" align="center" valign="middle"> 80 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 76 </td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 36 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 40 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Bladder </td>
<td class="Botrule Rrule" align="center" valign="middle"> 58 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 60 </td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 16 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 16 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Skin </td>
<td class="Botrule Rrule" align="center" valign="middle"> 37 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 37 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First">Rectal  </p> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 14 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 20 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="3" rowspan="2" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">Proctitis</span></td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Rrule" align="center" valign="middle">7</td>
<td class="Botrule Rrule" align="center" valign="middle">12</td>
</tr>
</tbody>
</table>
<p>Â </p>
<p>Additional adverse event data was collected for the combination therapy with radiation group over both the hormonal treatment and hormonal treatment plus radiation phases of the study. Adverse experiences occurring in more than 5% of patients in this group, over both parts of the study, were <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> (46%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (40%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9%), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> (8%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4805386-f123-4ca3-9427-1de439920c38"></a><a name="section-7.2"></a><p></p>
<h2>Stage D<span class="Sub">2</span> Metastatic Carcinoma</h2>
<p class="First">The following adverse experiences were reported during a multicenter clinical trial comparing flutamide capsules + LHRH agonist versus placebo + LHRH agonist.</p>
<p>The most frequently reported (greater than 5%) adverse experiences during treatment with flutamide capsules in combination with an LHRH agonist are listed in the table below. For comparison, adverse experiences seen with an LHRH agonist and placebo are also listed in the following table.</p>
<a name="id_8fb8a7f4-0b3d-495f-b71b-bc64c220165f"></a><table border="1">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<col align="left" width="1.00*">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Â </td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> (n = 294) </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> (n = 285) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â </td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> Flutamide + LHRH agonist </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> Placebo + LHRH agonist </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â </td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> % All </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"> % All </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 61 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 57 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">Loss of libido</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 36 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 31 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 33 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 29 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 12 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 4 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 11 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 10 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 9 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 11 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Other </td>
<td class="Botrule Rrule" align="center" valign="middle"> 7 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 9 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Other GI </td>
<td class="Rrule" align="center" valign="middle"> 6 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 4 </td>
</tr>
</tbody>
</table>
<p>As shown in the table, for both treatment groups, the most frequently occurring adverse experiences (<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>) were those known to be associated with low serum androgen levels and known to occur with LHRH agonists alone.</p>
<p>The only notable difference was the higher incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the flutamide + LHRH agonist group (12%), which was severe in 5% as opposed to the placebo + LHRH agonist (4%), which was severe in less than 1%.</p>
<p>In addition, the following adverse reactions were reported during treatment with flutamide + LHRH agonist.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac7cfbf5-ce18-4a59-8f4b-0e2e17db2619"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Bold">Cardiovascular System</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> in 1% of patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5166df2-5f7c-4fcd-9277-ac5c11129941"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="Bold">Central Nervous System</span></h3>
<p class="First">CNS (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>/<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>/<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>/<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>/<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>) reactions occurred in 1% of patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d0b154b-1ec9-49a1-8c9d-8732ad723cce"></a><a name="section-7.2.3"></a><p></p>
<h3><span class="Bold">Gastrointestinal System</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> 4%, and other GI disorders occurred in 6% of patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_366126fe-5ecf-45c1-a30e-c75ab7122cdc"></a><a name="section-7.2.4"></a><p></p>
<h3><span class="Bold">Hematopoietic System</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> occurred in 6%, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> in 3%, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in 1% of patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d973016a-638f-4a3b-a07b-f61a2125ecfc"></a><a name="section-7.2.5"></a><p></p>
<h3><span class="Bold">Liver and Biliary System</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> in less than 1% of patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d010144-5e61-4801-8a28-011b39f89b73"></a><a name="section-7.2.6"></a><p></p>
<h3><span class="Bold">Skin</span></h3>
<p class="First">Irritation at the injection site and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurred in 3% of patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d9d6ed4-9171-440d-9e76-1ab1a7843a0e"></a><a name="section-7.2.7"></a><p></p>
<h3><span class="Bold">Other</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> occurred in 4%, genitourinary and neuromuscular symptoms in 2%, and pulmonary symptoms in less than 1% of patients.</p>
<p>In addition, the following spontaneous adverse experiences have been reported during the marketing of flutamide: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">macrocytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="4137763" conceptname="Sulfhemoglobinemia">sulfhemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, ulceration, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span>, and <span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">epidermal necrolysis</span>), and <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span>. The urine was noted to change to an amber or yellow-green appearance which can be attributed to the flutamide and/or its metabolites. Also reported were <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>. The hepatic conditions were often reversible after discontinuing therapy; however, there have been reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following severe hepatic injury associated with use of flutamide.</p>
<p>Malignant breast neoplasms have occurred rarely in male patients being treated with flutamide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be650b3e-0a1d-4107-aa89-b6f91824ab6d"></a><a name="section-7.2.8"></a><p></p>
<h3><span class="Bold">Abnormal Laboratory Test Values</span></h3>
<p class="First">Laboratory abnormalities including elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, bilirubin values, SGGT, BUN, and serum creatinine have been reported.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_0e4a51a0-e3fc-42cb-9101-02672ed06cad"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In animal studies with flutamide alone, signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> included <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, slow respiration, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and/or <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, tranquilization, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, and <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
<p>Clinical trials have been conducted with flutamide in doses up to 1500 mg per day for periods up to 36 weeks with no serious adverse effects reported. Those adverse reactions reported included <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and some increases in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>. The single dose of flutamide ordinarily associated with symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or considered to be life-threatening has not been established.</p>
<p>Flutamide is highly protein bound and is not cleared by hemodialysis. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> does not occur spontaneously, it should be induced if the patient is alert. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b451ed7b-e2c3-4cf7-a2dc-9c074f866d7e"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage is 2 capsules 3 times a day at 8-hour intervals for a total daily dose of 750 mg.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_3cbddc7a-623e-4223-b46a-8908d7f10102"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Flutamide Capsules USP, 125 mg are available as light brown opaque oblong hard gelatin capsules, spin printed with </p>
<div class="Figure"><img alt="Company logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bae781d4-7101-4008-9af2-6e76b5e1c408&amp;name=55c76073-6224-4470-9426-2d5446f0781d-02.jpg"></div>
<p>and â€œ4960â€? in black ink containing 125 mg flutamide packaged in bottles of 180 and 500 capsules.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Manufactured In India By:</p>
<p><span class="Bold">CIPLA LTD.</span></p>
<p>Goa, India</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. A 1/2011</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_643fa6af-ffcc-4a59-873e-8e7aaa416a3a"></a><a name="section-11"></a><p></p>
<h1>Important Patient Information for Flutamide Capsules USP</h1>
<p class="First"><span class="Bold">Important information for patients taking flutamide capsules</span></p>
<p>Read this information carefully each time your prescription is refilled because there may be new information available. This summary does not tell you everything you need to know about flutamide therapy. Your doctor is the best source of information about your treatment. Ask your doctor about questions you have.</p>
<p><span class="Bold">What is flutamide therapy?</span></p>
<p>Flutamide, in combination with other therapies, is a treatment option for men with some types of prostate cancer.</p>
<p>Prostate cancer results from the abnormal growth of prostate cells. Medical scientists do not know exactly what causes the abnormal cells, but age, environment and genetics are important factors. Male hormones ("<span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>") cause the cancer to grow. The cancer growth can be slowed down by blocking the effect of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
<p>The flutamide product is used together with an injection called "LHRH agonist," as a combined treatment called "total androgen blockade." The goal of this treatment is to reduce androgen levels and to block the effect of androgen on the tumor. The LHRH agonist reduces androgen levels. Flutamide therapy blocks the effect of androgen on the tumor.</p>
<p><span class="Bold">Who should not take the flutamide product?</span></p>
<p>You should not take flutamide if you have liver problems or if you are allergic to it. Flutamide is for use only in men; therefore women should not take flutamide.</p>
<p><span class="Bold">Are there important risks I should know about flutamide therapy?</span></p>
<p>Some men taking the flutamide product had <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> and needed to be hospitalized. In rare cases, men died because of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> while they were taking flutamide. In about half of these cases, the <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> occurred in the first 3 months that they were taking flutamide.</p>
<p>Because the flutamide product may cause <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="Bold">it is very important that you have all blood tests recommended by your doctor</span>. These tests help identify whether you are having liver problems. A recommended schedule for these blood tests is:</p>
<ul>
<li>before starting flutamide treatment</li>
<li>every month for the first 4 months of therapy</li>
<li>periodically after the first 4 months</li>
</ul>
<p>In addition, you should call your doctor right away if you have any of the following signs or symptoms:</p>
<ul>
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>stomach or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (feeling extremely tired)</li>
<li>flu-like symptoms (<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, soreness)</li>
<li>brown urine</li>
<li><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (yellowing of the skin or whites of the eyes)</li>
</ul>
<p><span class="Bold">These may be signs of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</span></p>
<p><span class="Bold">How should I take flutamide capsules?</span></p>
<p>Take your flutamide capsules as your doctor has prescribed. The usual dosing is 2 capsules every 8 hours.</p>
<p>Your doctor will determine whether flutamide therapy is right for you based on many different factors. These include how large your tumor is, how far it has spread and your physical condition. In addition to flutamide, you may be getting other treatments, including regular injections of LH-RH agonist or radiation therapy. Do not stop or interrupt any treatment without consulting your healthcare professional.</p>
<p>If you miss a dose of flutamide capsules, simply continue therapy with your next scheduled dose. Do not try to make up for it by taking extra capsules.</p>
<p><span class="Bold">Can I take other medicines?</span></p>
<p>If you are taking any other medicines, especially warfarin (a blood-thinning drug), tell your doctor before beginning flutamide therapy.</p>
<p><span class="Bold">What are the other possible side effects of taking flutamide capsules?</span></p>
<p>In a medical study, when flutamide was taken together with an LHRH agonist, the most common side effects were <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, loss of sex drive (libido) and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>. In addition, some men had <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>.</p>
<p>In another medical study, when the flutamide product was taken together with goserelin acetate (an LHRH agonist) and radiation therapy, the side effects of flutamide were about the same as when radiation therapy was given alone. These included <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</p>
<p><span class="Bold">What can I do if I get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>?</span></p>
<p>If you experience moderate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to flutamide capsules, the following advice may help:</p>
<ul>
<li>drink plenty of fluids</li>
<li>reduce your intake of dairy products (for example, milk, cheese, yogurt)</li>
<li>increase your intake of whole grains, fruits, and vegetables</li>
<li>stop laxative use</li>
<li>take non-prescription anti-diarrheal medicines</li>
</ul>
<p>If your <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> continues or it becomes severe, contact your doctor right away.</p>
<p><span class="Bold">Are there any other lab tests my doctor will be performing?</span></p>
<p>Your doctor may perform other regular tests (such as the PSA blood test) to ensure that your body is responding to treatment. Ask your doctor if you have any questions about how your flutamide therapy is being monitored.</p>
<p><span class="Bold">Where can I get further support?</span></p>
<p>Please ask your doctor about any questions concerning prostate cancer or flutamide therapy, or you can also ask for a more detailed leaflet that is written for healthcare professionals.</p>
<p>Manufactured In India By:</p>
<p><span class="Bold">CIPLA LTD.</span></p>
<p>Goa, India</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. A 1/2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cf5b8a27-c4b3-4569-b0c5-78395a376331"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Flutamide Capsules USP 125 mg 180s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bae781d4-7101-4008-9af2-6e76b5e1c408&amp;name=55c76073-6224-4470-9426-2d5446f0781d-03.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e590cadd-380e-4015-82d7-03176efb1643"></a><a name="section-12.1"></a><p></p>
<h2>Flutamide Capsules USP 125 mg 180s Label Text</h2>
<p class="First">NDC 0172-4960-58</p>
<p>FLUTAMIDE</p>
<p>Capsules USP</p>
<p>125 mg</p>
<p>PHARMACIST: PLEASE DISPENSE WITH ATTACHED</p>
<p>PATIENT INFORMATION LEAFLET</p>
<p>Rx only</p>
<p>180 CAPSULES</p>
<p>TEVA</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUTAMIDEÂ 		
					</strong><br><span class="contentTableReg">flutamide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0172-4960</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUTAMIDE</strong> (FLUTAMIDE) </td>
<td class="formItem">FLUTAMIDE</td>
<td class="formItem">125Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4960</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0172-4960-60</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0172-4960-58</td>
<td class="formItem">180  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0172-4960-70</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075780</td>
<td class="formItem">09/19/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>IVAX Pharmaceuticals, Inc.
							(884075235)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>55c76073-6224-4470-9426-2d5446f0781d</div>
<div>Set id: bae781d4-7101-4008-9af2-6e76b5e1c408</div>
<div>Version: 5</div>
<div>Effective Time: 20120831</div>
</div>
</div>Â <div class="DistributorName">IVAX Pharmaceuticals, Inc.</div></p>
</body></html>
